Videos

Learn how coaching, EHR reminders, and home kits boost colon cancer screening—plus when stool, colonoscopy, or blood tests fit best.

ACOG 2026: CDC data show many pregnancy-related deaths may be preventable through better care coordination, access, and follow-up.

A breast cancer survivor on anastrozole struggles with relentless hot flashes and insomnia—explore evidence-based, nonhormonal relief options.

In "Novel Non-Hormonal Therapies for VMS: Mechanisms and Clinical Evidence," our panel explores the neurophysiology underlying vasomotor symptoms and the clinical significance of two FDA-approved neurokinin receptor antagonists that represent a meaningful advance in non-hormonal VMS treatment.

In this episode, "Navigating Menopausal Hormone Therapy Safety in VMS," the experts explore the nuances of menopausal hormone therapy (MHT) safety, addressing persistent misconceptions that have affected both clinical practice and patient decision-making since the FDA's black box warning.

Clinicians break down hot flash impact and compare lifestyle, hormone, SSRI/SNRI, and new NK3 therapies using real patient cases.

Compare FIT, FOBT, Cologuard, and colonoscopy for colorectal cancer screening—test intervals, sensitivity, and key prep tips, including GLP-1 and anticoagulant holds.

Compare stool-based colorectal cancer screening options, from FIT and occult blood tests to Cologuard, plus colonoscopy prep tips for GLP-1s and blood thinners.

Despite waning direct impact of COVID-19, US pregnancy-related mortality remains higher than before the pandemic, driven by persistent cardiovascular, infectious, and hemorrhagic causes.

Leslie Citrome, MD, on new NEI Spring Congress data on adjunctive lumateperone for major depressive disorder and how clinicians can weigh efficacy, tolerability, and next-step treatment decisions.

This episode, titled "Hormonal and Non-Hormonal Treatment Options in VMS," features panelists walking through the full spectrum of evidence-based treatment options for vasomotor symptoms, grounded in The Menopause Society position statement and decades of clinical and research experience.

In "Cardiovascular Risk Assessment and VMS Management in Menopausal Care," our panel explores the inadequacies in current cardiovascular risk assessment practices for menopausal women and presents a comprehensive, guideline-informed framework for improving that care.

Highlights include time-efficient strategies for primary care clinicians to identify, assess, and treat GSM and other sexual health concerns during menopause.

ACOG 2026: Kathryn Miele, MD, discusses syphilis screening in pregnancy and how clinicians can reduce stigma around testing.

ACOG 2026: Kathryn Miele, MD, discusses syphilis titer interpretation, discordant results, partner treatment, and practical resources for primary care clinicians.

Compare colonoscopy, CT, stool DNA and blood tests for colorectal cancer screening—accuracy, intervals,

Compare colonoscopy, CT and stool DNA tests for colorectal cancer screening: accuracy, timing, and why pairing methods can raise detection.

Pneumococcal vaccination in pregnancy remains underused in high-risk patients. Maria Marcos, MD, reviews new data, barriers to uptake, and practical vaccination steps for primary care.

Jill Liss, MD, outlines how updated evidence, risk stratification, and newer nonhormonal agents can help PCPs confidently manage VMS in everyday practice.

ACOG 2026: James A. Simon, MD, discusses off-label evidence for elinzanetant in breast cancer survivors on anti-estrogenic therapy.

ACOG 2026: James A. Simon, MD, discusses what the results mean for frontline clinician confidence in prescribing the non-hormonal VMS treatment.

In this episode, "VMS and Cardiovascular Risk: Mechanisms, Risk Factors, and Prevention," the experts explore the underlying mechanisms that connect vasomotor symptoms to increased cardiovascular risk and discuss how clinicians across specialties can better identify and address that risk. Dr. Erin Michos outlines several proposed pathophysiological pathways linking VMS to cardiovascular disease. Women with more severe VMS tend to present with worse cardiometabolic profiles, including elevated blood pressure, insulin resistance, adverse lipid levels, and metabolic syndrome. VMS are also discussed as potential markers of endothelial dysfunction, evidenced by reduced flow-mediated dilation, as well as autonomic nervous system dysregulation — characterized by increased sympathetic and decreased parasympathetic tone. Additionally, HPA axis dysregulation, reflected in blunted morning cortisol and elevated urinary cortisol, may further explain the cardiovascular association.

Welcome back to another Patient Care Online Peers & Perspectives series. The segment opens with introductions from moderator, Dr. Kristi DeSapri, a board-certified internist with fellowship training in midlife and menopause care, and panelist, Dr. Erin Michos, a cardiologist who directs a women's cardiovascular health and multidisciplinary menopause program. The discussion centers on vasomotor symptoms (VMS) — clinically defined as hot flashes and night sweats — and their broad effects on women's health during the menopausal transition.

ACOG 2026: Jill Liss, MD, details how primary care physicians can safely initiate hormone therapy, manage menopause counseling in brief visits, and more.

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

Rising colorectal cancer in younger adults shifts primary care: start screening at 45, spot red flags, choose the right tests for patients.

Learn why colon cancer rises in younger adults, when to start screening at 45, and how primary care chooses the right tests.

A new oral hair loss pill just cleared phase 2/3 trials. Study investigator Michael Gold, MD, breaks down how VDPHL01 compares to minoxidil and finasteride.

Rachael Sood, NP-C, CDCES, outlines what the FDA clearance of Control-IQ+ for type 1 diabetes in pregnancy means for primary care practice.

6-month INFUSE data show eptinezumab improves migraine outcomes, including headache days and patient-reported measures, even after prior CGRP failures.